We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MEDICIS AND IPSEN DECIDE TO FOCUS PARTNERSHIP FOR RELOXIN EXCLUSIVELY ON UNITED STATES, CANADA AND JAPAN
MEDICIS AND IPSEN DECIDE TO FOCUS PARTNERSHIP FOR RELOXIN EXCLUSIVELY ON UNITED STATES, CANADA AND JAPAN
July 12, 2006
Ipsen and Medicis today announced that they will not pursue an agreement for
the commercialization of Ipsen's botulinum toxin product, Reloxin, outside of
the United States, Canada and Japan.
